Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics to Participate in Upcoming Investor Conferences

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AngioDynamics, Inc. announced its participation in upcoming investor conferences, including the UBS Global Healthcare Conference on November 9, 2026. The company aims to engage with investors and discuss its focus on medical technology that enhances blood flow and cancer treatment options. This participation reflects AngioDynamics' commitment to improving patient quality of life.

Market Sentiment Analysis

POSITIVE FACTORS

  • AngioDynamics is participating in key investor conferences.
  • The company focuses on innovative medical technologies.
  • Management engagement with investors is scheduled.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
RF ablation
Phase 2 · Non Small Cell Lung Cancer

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 9, 2026, from 8:00-8:35 AM ET Canaccord Genuity's MedT

Frequently Asked Questions

What conferences will AngioDynamics attend?

AngioDynamics will attend the UBS Global Healthcare Conference on November 9, 2026.

What is AngioDynamics focused on?

The company focuses on restoring blood flow and expanding cancer treatment options.

When is the UBS Global Healthcare Conference?

The conference is scheduled for November 9, 2026, from 8:00-8:35 AM ET.

Who will represent AngioDynamics at the conferences?

Management from AngioDynamics will participate in the investor conferences.

ShareAdd on Google
Tags: ANGO AngioDynamics investor conference UBS Global Healthcare medical technology NASDAQ: ANGO
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$34M liquidity · $5M/mo burn
~6 mo
Medium dilution risk
Lead asset
RF ablationPhase 2
Non Small Cell Lung Cancer →